Gilead Sciences Price to Free Cash Flow Ratio 2006-2021 | GILD

Historical price to free cash flow ratio values for Gilead Sciences (GILD) since 2006. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Gilead Sciences Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-25 68.84 9.16
2021-09-30 69.15 $7.51 9.21
2021-06-30 67.49 $6.70 10.08
2021-03-31 62.69 $6.89 9.09
2020-12-31 55.87 $5.95 9.39
2020-09-30 59.92 $6.41 9.35
2020-06-30 72.22 $6.71 10.75
2020-03-31 69.52 $6.47 10.75
2019-12-31 59.83 $6.51 9.18
2019-09-30 57.82 $6.29 9.19
2019-06-30 61.05 $5.91 10.34
2019-03-31 58.20 $5.20 11.19
2018-12-31 55.46 $5.72 9.70
2018-09-30 67.88 $6.04 11.25
2018-06-30 61.81 $6.41 9.65
2018-03-31 65.26 $8.01 8.15
2017-12-31 61.57 $8.57 7.18
2017-09-30 69.15 $9.00 7.68
2017-06-30 60.03 $10.27 5.84
2017-03-31 57.14 $11.33 5.04
2016-12-31 59.79 $12.00 4.98
2016-09-30 65.65 $13.24 4.96
2016-06-30 68.80 $12.74 5.40
2016-03-31 75.34 $12.73 5.92
2015-12-31 82.60 $13.48 6.13
2015-09-30 79.60 $11.59 6.87
2015-06-30 94.79 $11.32 8.37
2015-03-31 79.16 $10.16 7.79
2014-12-31 76.03 $7.44 10.21
2014-09-30 85.87 $6.13 14.00
2014-06-30 66.88 $4.11 16.25
2014-03-31 57.16 $2.18 26.28
2013-12-31 60.58 $1.72 35.22
2013-09-30 50.71 $1.61 31.48
2013-06-30 41.36 $1.60 25.87
2013-03-31 39.48 $1.87 21.09
2012-12-31 29.62 $1.77 16.76
2012-09-30 26.75 $2.07 12.89
2012-06-30 20.68 $2.22 9.31
2012-03-31 19.71 $2.00 9.86
2011-12-31 16.51 $2.22 7.44
2011-09-30 15.65 $2.00 7.82
2011-06-30 16.70 $1.92 8.72
2011-03-31 17.13 $1.73 9.91
2010-12-31 14.62 $1.59 9.21
2010-09-30 14.36 $2.39 6.02
2010-06-30 13.83 $1.69 8.16
2010-03-31 18.34 $1.63 11.27
2009-12-31 17.45 $1.53 11.44
2009-09-30 18.75 $0.64 29.19
2009-06-30 18.89 $1.12 16.94
2009-03-31 18.68 $1.01 18.56
2008-12-31 20.63 $1.06 19.50
2008-09-30 18.40 $0.98 18.76
2008-06-30 21.36 $0.85 25.09
2008-03-31 20.78 $0.89 23.42
2007-12-31 18.56 $0.82 22.50
2007-09-30 16.48 $0.86 19.10
2007-06-30 15.65 $0.86 18.17
2007-03-31 15.46 $0.74 20.89
2006-12-31 13.09 $0.61 21.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $86.013B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.972B 8.78
Bio-Rad Laboratories (BIO.B) United States $16.992B 34.48
QIAGEN (QGEN) Netherlands $11.128B 18.85
Biohaven Pharmaceutical Holding (BHVN) United States $7.780B 0.00
Emergent Biosolutions (EBS) United States $2.486B 8.94
Arcus Biosciences (RCUS) United States $2.230B 0.00
Myovant Sciences (MYOV) United Kingdom $1.231B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.064B 0.00
Zymeworks (ZYME) Canada $0.466B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Ambrx Biopharma (AMAM) United States $0.193B 0.00
Enzo Biochem (ENZ) United States $0.153B 19.75